Corneal Refractive Procedures for the Treatment of Presbyopia

Moussa, Kareem; Jehangir, Naz; Mannis, Tova; Wong, Wai Ling; Moshirfar, Majid

doi:10.2174/1874364101711010059

Cited by 9 publications

(8 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…nondominant eye is made slightly myopic (mini or micro monovision) [12]. Reported success rates of PresbyLASIK vary; furthermore, the evidence is limited by a lack of standardized outcome measures and long-term follow-up [11,12].…”

Section: Key Pointsmentioning

confidence: 99%

Pilocarpine 1.25% and the changing landscape of presbyopia treatment

Meghpara

Lee

Rapuano

et al. 2022

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

Purpose of reviewDespite affecting approximately 1.8 billion individuals worldwide, until recently, a pharmacologic treatment for presbyopia was not available. This special commentary reviews the treatment of presbyopia with a focus on the recently approved medication Vuity (pilocarpine 1.25%, Allergan, an AbbVie Company).Recent FindingsVuity is a re-engineered formulation of pilocarpine 1.25% specifically designed for the treatment of presbyopia. Recently published results from the GEMINI 1 Phase 3 clinical trial reported improvement in distance corrected near vision without significant compromise in distance vision. No unexpected safety findings were reported with mild headache being the most common adverse event. Notably, there were no reported cases of retinal detachment or angle closure during the 30-day phase 3 clinical trials.SummaryVuity is the first treatment designed and FDA approved to treat the growing presbyopia market. Phase 3 clinical trials demonstrated its ability to improve near vision without significant compromise in distance vision. We recognize this paradigm shift in the treatment of presbyopia and anxiously await additional treatment options for this ubiquitous condition.

show abstract

Section: Key Pointsmentioning

confidence: 99%

Pilocarpine 1.25% and the changing landscape of presbyopia treatment

Meghpara

Lee

Rapuano

et al. 2022

Current Opinion in Ophthalmology

View full text Add to dashboard Cite

show abstract

“…2,3,4,5,6 Previous studies have compared different types of presbyopic corrections and have suggested that PALs are the most acceptable solution. 7,8,9,10 A PAL is designed to provide continuous vision at all required viewing distances (distance, intermediate and near). 1,5 Progressive lenses ensure the optimal dioptric power for every distance that the presbyopic spectacle wearer requires, for smooth and uninterrupted vision without any visible lines of demarcation.…”

Section: Introductionmentioning

confidence: 99%

Progressive addition lenses wearers’ visual satisfaction among Saudi population

Elmadina

2022

African Vision and Eye Health

View full text Add to dashboard Cite

Background: Progressive additive lenses (PALs) are an increasingly prescribed form of optical compensation to correct refractive error with presbyopia but sometimes with noticeable restrictions that can reduce visual satisfaction. Aim:The current study evaluated vision satisfaction rate and any associated problems among Saudi PAL wearers. Setting:The study was conducted in Al-Qassim and Al-Riyadh regions, Saudi Arabia.Methods: A cross-sectional design was used with a Likert-scale questionnaire survey (LQS) in this study. Data were analysed using Statistical Package for Social Sciences (SPSS) software version 21, Graphpad Prism, and MS Excel programmes, and p < 0.05 was considered statistically significant.Results: One hundred and thirty-eight Saudi PALs wearers (87 men [63%] and 51 women [37%]) aged over 40 years participated in the study. Participants completed an online questionnaire concerning their levels of visual satisfaction and reported any complaints while using PALs. The overall results indicated high levels of satisfaction with comfortable vision in all tasks (median = 4 on LQS) with 55% overall vision satisfaction (p = 0.001). A strong association was found between the overall vision satisfaction and seeing when driving, and, also, with reading (p < 0.001). The length of time since starting the use of PALs was found to be significantly (p = 0.001) associated with overall satisfaction and associated complaints, while gender and age had no impact on overall vision satisfaction. Conclusion:Saudi PAL wearers possess a good level of visual satisfaction while experiencing some difficulties and complaints when using their PALs. Gender and age were not factors that impacted overall visual satisfaction and complaints; however, time since starting to wear PALs was a factor.

show abstract

“…External ocular lenses, such as spectacles or contact lenses, are typically used to correct vision [1]. Ocular surgery and surgical devices, such as corneal inlays [3], multifocal or extended depth of field (EDOF) intra-ocular lenses [4][5][6] and refractive laser [7,8] can also be used as treatment options, but these are invasive procedures, they are expensive and some treatments can only treat one eye (monovision) with a loss of optical summation from binocular vision [1,[3][4][5][6][7][8]. Access to spectacles is also problematic in developing countries, where 94% of presbyopic subjects reside [2].…”

Section: Introductionmentioning

confidence: 99%

Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial

Korenfeld

Robertson²,

Stein³

et al. 2021

Eye

View full text Add to dashboard Cite

Objectives This study evaluated the safety of topical lipoic acid choline ester (UNR844, 1.5%) ophthalmic solution and its efficacy in improving distance-corrected near visual acuity (DCNVA) in subjects with presbyopia. Subjects and methods This was a prospective, randomized, double-masked, and multicentre clinical trial. Subjects with a diagnosis of presbyopia (n = 75) were randomized 2:1 to UNR844 or placebo. On days 1–7, all subjects were dosed unilaterally (twice a day, b.i.d.) in their non-dominant eye to ensure safety and tolerability prior to days 8–91 when dosing was changed to bilateral (b.i.d.). Clinical assessments, including DCNVA and adverse events (AEs), were recorded at each study visit. Patients who completed the study were recruited into a non-interventional follow-up study that monitored them until 7 months after their final UNR844 exposure. The primary endpoints were safety and the mean change in DCNVA from baseline in the study eye. Results UNR844 administration (n = 50) produced no safety concerns and was well-tolerated, with no clinically-relevant changes in best-corrected distance visual acuity, pupil size, intraocular pressure, or discontinuations due to adverse events. DCNVA improved in the study eye in the UNR844 group compared to placebo during the 91 days of treatment [UNR844 vs. placebo, mean change in LogMAR (SD); −0.159 (0.120) vs. −0.079 (0.116)]. Bilateral DCNVA improved, with 53.1% UNR844 vs. 21.7% placebo subjects gaining ≥10 letters. Improvements in DCNVA were sustained at 5 and 7 months after UNR844 dosing ceased. Conclusions These results support further development of UNR844 ophthalmic solution for the treatment of presbyopia.

show abstract

Corneal Refractive Procedures for the Treatment of Presbyopia

Cited by 9 publications

References 76 publications

Pilocarpine 1.25% and the changing landscape of presbyopia treatment

Pilocarpine 1.25% and the changing landscape of presbyopia treatment

Progressive addition lenses wearers’ visual satisfaction among Saudi population

Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial

Contact Info

Product

Resources

About